Results 161 to 170 of about 26,436 (212)

Transarterial infusion chemotherapy combined with lenvatinib and tislelizumab versus intravenous chemotherapy for unresectable pancreatic ductal adenocarcinoma: a retrospective propensity score matching analysis. [PDF]

Front Oncol
Lu H, Liang B, Fu Q, Xia X.
europepmc   +1 more source

HAIC combined with lenvatinib and tislelizumab for HCC with concurrent PVTT and pulmonary metastasis: a multicenter propensity score matching analysis. [PDF]

Ther Adv Med Oncol
Chen S, Wu Z, Xiao Y, Jiang X, Shi F, Wang N, Lin F, Tan G, Zhuang W, Huang Y.   +9 more
europepmc   +1 more source

Clinical Outcomes of Lenvatinib-Pembrolizumab in a High-Risk, Dual ICI-Refractory Melanoma Cohort. [PDF]

Clin Med Insights Oncol
Geçgel A, Gökdere ZS, Özüdoğru T, Mıdık MM, Karaca B.   +4 more
europepmc   +1 more source

Farnesyl Transferase Inhibitor KO-2806 (Darlifarnib) Enhances the Antitumor Activity of Tyrosine Kinase Inhibitors in RCC. [PDF]

Mol Cancer Ther
Gasendo JG, Chan S, Patel HV, Smith AE, Kessler L, Liu YA, Mitra A, Burrows F, Malik S.   +8 more
europepmc   +1 more source

Nivolumab Plus Lenvatinib and Intra-Arterial Locoregional Therapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Real-World Study. [PDF]

J Hepatocell Carcinoma
Gu S, Zhao Y, Yan H, Li M, Li G, Huang M, Xiong Z, Huang B.   +7 more
europepmc   +1 more source

How to manage radioiodine-refractory thyroid cancer in the era of precision medicine. [PDF]

Drugs Context
Karapanou O, Effraimidis G, Michalaki M, Saltiki K.   +3 more
europepmc   +1 more source

[Retracted] Combined effects of Lenvatinib and iodine-131 on cell apoptosis in nasopharyngeal carcinoma through inducing endoplasmic reticulum stress. [PDF]

Exp Ther Med
Wang G, Zhuang J, Ni J, Ye Y, He S, Xiai W.   +5 more
europepmc   +1 more source